Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.07. | Transkript des Earnings Calls: Elite Pharma verzeichnet 52% Umsatzwachstum in Q1 2025 | 3 | Investing.com Deutsch | ||
01.07. | Elite Pharmaceuticals reports FY results | 3 | Seeking Alpha | ||
30.06. | ELITE PHARMACEUTICALS INC /NV/ - 8-K, Current Report | 3 | SEC Filings | ||
30.06. | Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information | 246 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
ELITE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
30.06. | ELITE PHARMACEUTICALS INC /NV/ - 10-K, Annual Report | 5 | SEC Filings | ||
23.06. | ELITE PHARMACEUTICALS INC /NV/ - 8-K, Current Report | 2 | SEC Filings | ||
23.06. | Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025 | 205 | Newsfile | Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic... ► Artikel lesen | |
16.06. | ELITE PHARMACEUTICALS INC /NV/ - 8-K, Current Report | 17 | SEC Filings | ||
16.06. | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study | 272 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
30.04. | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | 513 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
03.03. | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | 301 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
03.03. | ELITE PHARMACEUTICALS INC /NV/ - 8-K, Current Report | 7 | SEC Filings | ||
13.02. | Elite Pharmaceuticals reports Q3 results | 2 | Seeking Alpha | ||
13.02. | Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information | 334 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
13.02. | ELITE PHARMACEUTICALS INC /NV/ - 8-K, Current Report | - | SEC Filings | ||
13.02. | ELITE PHARMACEUTICALS INC /NV/ - 10-Q, Quarterly Report | 3 | SEC Filings | ||
10.02. | Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025 | 292 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
26.12.24 | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R) | 726 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
02.12.24 | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets | 282 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
18.11.24 | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse | 427 | Newsfile | Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 27,670 | -1,07 % | Aktien der Woche: BASF, Bayer, Deutsche Rohstoff / Almonty, Evotec, Rheinmetall, Renk | Sechs Aktien sorgten in dieser Woche für Schlagzeilen - mit Kurssprüngen, Analystenreaktionen oder überraschenden Unternehmensmeldungen. Die 4investors-Redaktion zeigt, welche Titel in den letzten Tagen... ► Artikel lesen | |
NOVO NORDISK | 55,56 | +0,34 % | BERENBERG stuft NOVO NORDISK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Novo Nordisk mit einem Kursziel von 610 dänischen Kronen auf "Hold" belassen. Nach der ereignislosen ADA-Konferenz (American... ► Artikel lesen | |
PFIZER | 21,030 | -0,10 % | Diese Aktie zeigt die wissenschaftliche Schlagkraft hinter ihrer KI-gesteuerten Krebsforschung | ||
NOVARTIS | 99,13 | +0,32 % | DAX startet freundlich - TSMC und Novartis im Fokus | ||
MERCK KGAA | 110,60 | -0,85 % | Verhaltene Kauflaune bei Merck KGaA-Aktie (112,35 €) | Wenig Kursbewegung derzeit bei dem Anteilsschein von Merck . Der jüngste Kurs betrug 112,35 Euro. Der Kurs der Aktie von Merck zeigt sich aktuell kaum verändert im Vergleich zu der letzten Notierung... ► Artikel lesen | |
GILEAD SCIENCES | 93,57 | +0,50 % | Gilead Sciences Presents New Data On Twice-Yearly Lenacapavir For HIV Prevention | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) Monday announced that Gilead researchers and collaborators will present new Phase 3 Purpose trial data at IAS 2025 showing that twice-yearly... ► Artikel lesen | |
AURORA CANNABIS | 3,890 | -0,38 % | Stocks in Play: Aurora Cannabis Inc. | ||
SANOFI | 83,04 | +0,02 % | Thermo Fisher übernimmt Sterilproduktion von Sanofi in den USA | Der US-Laborausrüster Thermo Fisher Scientific erweitert seine Produktionsinfrastruktur und übernimmt die Sterilfabrik von Sanofi im US-Bundesstaat New Jersey. Das Werk in Ridgefield soll künftig das... ► Artikel lesen | |
GSK | 15,655 | -4,48 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1450 Pence auf "Hold" belassen. Ein mögliches "Revival" des Medikaments Blenrep gegen Knochenmarkkrebs... ► Artikel lesen | |
ABBVIE | 162,40 | -0,37 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
CANOPY GROWTH | 0,952 | -0,10 % | Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? | ||
ROCHE | 277,60 | +0,40 % | JPMORGAN stuft ROCHE HOLDINGS AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche vor den am 24. Juli erwarteten Quartalszahlen mit einem Kursziel von 220 Franken auf "Underweight" belassen. Richard Vosser... ► Artikel lesen | |
STADA ARZNEIMITTEL | - | - | NEXGEL, INC.: NEXGEL and STADA AG Announce Expansion of Partnership for North America | LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare... ► Artikel lesen | |
MERCK & CO | 68,80 | 0,00 % | Merck's EZMEKLY Secures Conditional Marketing Authorization From European Commission | KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), Friday announced that the company has secured conditional marketing authorization from the European Commission for EZMEKLY for the treatment... ► Artikel lesen | |
ELI LILLY | 663,10 | -2,28 % | Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? |